nVerses Capital LLC Invests $103,000 in Cellebrite DI Ltd. (NASDAQ: CLBT)

nVerses Capital LLC purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,600 shares of the company’s stock, valued at approximately $103,000.

A number of other large investors have also added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Cellebrite DI by 78.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,862 shares of the company’s stock worth $233,000 after purchasing an additional 11,771 shares in the last quarter. Josh Arnold Investment Consultant LLC purchased a new position in shares of Cellebrite DI during the 4th quarter worth $346,000. IGP Investments GPLP LP purchased a new position in shares of Cellebrite DI during the 4th quarter worth $182,619,000. Trexquant Investment LP increased its stake in Cellebrite DI by 297.1% in the 4th quarter. Trexquant Investment LP now owns 261,749 shares of the company’s stock worth $2,267,000 after acquiring an additional 195,841 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in Cellebrite DI in the 4th quarter worth approximately $243,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price-performance

CLBT opened at $16.95 on Wednesday. The company has a market cap of $3.49 billion, a price/earnings ratio of -29.22, a price/earnings growth ratio of 2.35, and a beta of 1.52. Cellebrite DI Ltd. has a one-year low of $6.36 and a one-year high of $17.48. The company has a 50-day moving average price of $13.83 and a 200-day moving average price of $12.20.

Cellebrite DI (NASDAQ: CLBT – Get Free Report) last released its quarterly earnings results on Thursday, August 15. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company’s quarterly revenue increased by 24.8% year-over-year. In the same quarter last year, the company earned $0.05 EPS. On average, analysts expect Cellebrite DI Ltd. to post 0.31 EPS for the current year.

Analyst Upgrades and Downgrades

CLBT has been the subject of a number of research reports. Needham & Company LLC increased their price target on shares of Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Bank of America increased their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Craig Hallum increased their price target on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday, August 16th. Lake Street Capital increased their price target on Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. their price objective on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Seven research analysts have rated the stock with a “buy” rating. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price objective of $17.33.

Get our latest analysis on Cellebrite DI

About Cellebrite DI

(Free Report)

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.